Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Stopped early · Phase 3

Conditions studied: Parkinson's Disease

In brief

The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.

Key facts

Study ID

NCT00519532

Run by

UCB Pharma

People needed

84

Starts

2007-07-01

Expected to finish

2009-05-01

Last updated by the study team

2014-10-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of trial SP889

You may not qualify if…

• Ongoing serious adverse event assessed as related to trial medication

Where it is running

• Study site — St. Petersburg, Florida, United States
• Study site — Salisbury, North Carolina, United States
• Study site — Concord, Australia
• Study site — Oulu, Finland
• Study site — Berlin, Germany
• Study site — Dresden, Germany
• Study site — Kassel, Germany
• Study site — Marburg, Germany
• Study site — Naumburg, Germany
• Study site — Ulm, Germany
• Study site — Budapest, Hungary
• Study site — Nyíregyháza, Hungary
• Study site — Chieti, Italy
• Study site — Milan, Italy
• Study site — Christchurch, New Zealand
• Study site — Olyszytn, Poland
• Study site — Cape Town, South Africa
• Study site — Barcelona, Spain
• Study site — Madrid, Spain
• Study site — Lancashire, United Kingdom
• Study site — Liverpool, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.